CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized phase II non comparative study. Patients with metastatic Neuroendocrine
Carcinomas (NEC) Grade 3, will be enrolled in the study and will be randomly assigned to
receive FOLFIRI or CAPTEM as second line treatment. Disease control rate (DCR) and safety are
primary objectives, secondary objectives are Disease control rate (OS), Progression Free
Survival (PFS), quality of life and toxicity of subsequent line of therapy (after Progression
Disease PD) with an observational purpose.
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori